In-Plane Ultrasound-Guided Botulinum Toxin Injection to Lumbrical and Interosseus Upper Limb Muscles: Technical Report

This technical report presents an innovative approach utilizing in-plane ultrasound-guided injections to precisely target the lumbrical and interosseous muscles within the upper limb. The report also elucidates the rationale and advantages of incorporating ultrasound guidance in the administration of Botulinum toxin (BTX) injections, encompassing the real-time visualization of needle trajectory and accurate localization of the target muscle groups while delving into the pertinent anatomical details of these muscles and their significance in diverse neuromuscular conditions. The step-by-step procedure for conducting in-plane ultrasound-guided BTX injections to the lumbrical and interosseous muscles is delineated, emphasizing critical technical considerations and potential pitfalls to be vigilant of during the procedure. Furthermore, the article addresses the significance of selecting appropriate BTX dosages and injection sites based on individual patient presentations and clinical indications. Overall, the in-plane ultrasound-guided BTX injection technique presents a promising approach for providing precise and targeted treatment to the lumbrical and interosseous muscles in the upper limb. It offers clinicians an alternative to injections performed without guidance or out-of-plane ultrasound-guided injections, potentially decreasing the likelihood of complications and enhancing treatment outcomes for patients with a range of neuromuscular conditions. However, further research and comparative studies are necessary to establish the long-term efficacy and safety of this technique, thus confirming its role in clinical practice.

Correlation between Cardiopulmonary Indices and Running Performance in a 14.5 km Endurance Running Event

BACKGROUND

Running is a common recreational activity, and the number of long-distance-race participants is continuously growing. It is well-established that regular physical activity can prevent and manage non-communicable diseases and benefit public health. Training for a long-distance race requires development of specific aerobic abilities and should generate the desired race performance. The purpose of this study was to support the training design and motivation of recreational endurance runners, by investigating whether a 14.5 km race performance of long-distance runners correlates with their cardiopulmonary indices measured in the laboratory.

METHODS

To examine the relationships of a 14.5 km running performance with the cardiopulmonary parameters of amateur runners, a cross-sectional study design was applied. Fifteen (eleven men and four women) recreational long-distance runners (aged 41.3 ± 9.2 years) from Northern Greece were included in the study and were evaluated in the laboratory within one week before an endurance running race-the 14.5 km Philip Road race, in Greece. The laboratory-based examinations of the athletes consisted of a comprehensive medical pre-participation screening and maximal cardiopulmonary exercise testing.

RESULTS

The results showed that the 14.5 km race performance time (73.8 ± 9.7 min) significantly correlated with the cardiopulmonary-exercise-testing speed-related indices at specific submaximal and maximal workloads (p < 0.01, p < 0.05), while the cardiopulmonary indices of oxygen uptake did not reliably predict race running time (p > 0.05).

CONCLUSIONS

There is a better correlation of the 14.5 km running performance of recreational long-distance runners with the cardiopulmonary-exercise-testing speed-related indices at specific workloads than with the indices of oxygen uptake, running economy or respiratory economy. When preparing a training strategy, amateur long-distance runners should mostly rely on specific running-speed-related laboratory data rather than on oxygen-uptake values.

Isolated Obturator Internus Muscle Strain Injury in a Professional Football Player: A Case Report

The present case report concerns an isolated obturator internus muscle strain. The patient, who was a 30-year-old professional, elite-level football player, suffered the injury during the warm-up before a football match. Isolated injuries of the obturator internus are very uncommon and they are extremely rarely reported in the literature. The diagnosis was made clinically, documented by magnetic resonance imaging. The rehabilitation program was conducted conservatively with physical therapy and kinesiotherapy. The patient’s return to full athletic activity took place 2 weeks after the incident.

Amineptine induced liver injury. Report of two cases and brief review of the literature

Two cases of amineptine induced liver injury in patients treated with the drug for 18 and 15 days respectively, are reported. Hepatic reaction lasted 60 days in the first case and 120 days in the second one, with the latter considered unusually prolonged. The patients history, the course of the reaction and the histologic findings were compatible with the diagnosis of drug induced liver disease in both cases. Furthermore, every other possible origin of hepatobiliary injury such as disorders of bile ducts, ongoing viral hepatitis and autoimmune hepatitis were excluded. The mechanism of amineptine induced liver injury and the influence of a possible genetic predisposition to amineptine hepatotoxicity are also discussed.

Recombinant human interferon alfa-2b treatment for acute non-A, non-B hepatitis

To assess the safety and possible efficacy of recombinant human interferon alfa-2b in preventing the development of chronic hepatitis, 24 adults (eight men, 16 women) with acute non-A, non-B (NANB) hepatitis were recruited to a pilot study. Half of the cases were parenterally transmitted and half were community acquired. Twelve patients received 3 million units (MU) interferon three times weekly subcutaneously for six weeks and the remaining 12 patients received no treatment. Anti-hepatitis C virus (HCV) was detected in 14 (58.3%) of the 24 patients. The alanine aminotransferase activity returned to normal in nine of 12 interferon alfa-2b treated patients and six of 12 controls by week 52. Interferon alfa-2b was well tolerated, even in jaundiced patients, who only complained of mild flu like syndrome during the first week of treatment. These data are consistent with the hypothesis that interferon alfa-2b may help prevent progression to chronic hepatitis (interferon alfa-2b 25% v controls 50%), particularly in anti-HCV negative cases (interferon alfa-2b none of six v controls two of four). A randomised, double blind placebo-controlled trial is required, however, to substantiate these results further.